ANVISA approved new regulatory requirements governing the issuance of electronic prescriptions for controlled medicines, marking a significant step toward digitalization and enhanced regulatory oversight of controlled substances in Brazil.
The approved requirements establish the technical and regulatory conditions for issuing, validating, and managing electronic prescriptions, aiming to ensure traceability, authenticity, and patient safety while supporting the modernization of prescribing practices.
Key Highlights
- Electronic Prescription Framework
Establishes formal requirements for issuing prescriptions for controlled medicines in electronic format and defines conditions to ensure authenticity, integrity, and traceability. - Controlled Medicines Oversight
Applies to medicines subject to special control, reinforcing regulatory supervision over prescribing and dispensing activities and strengthening monitoring mechanisms to prevent misuse and diversion. - Digitalization and Compliance
Supports the transition from paper-based prescriptions to secure electronic systems, enhancing regulatory efficiency while maintaining compliance with controlled substances regulations. - Operational Impact
Affects healthcare professionals, pharmacies, and entities involved in prescribing and dispensing controlled medicines, requiring alignment of internal systems and processes with the approved electronic prescription requirements.
This regulatory update reinforces Brazil’s commitment to digital transformation in healthcare while maintaining robust regulatory controls over controlled medicines.
Select Mandate HA
Select Mandate Function